Abliva AB (publ)

SSE:ABLI.ST

0.24 (SEK) • At close February 20, 2024
Bedrijfsnaam Abliva AB (publ)
Symbool ABLI.ST
Munteenheid SEK
Prijs 0.238
Beurswaarde 250,871,250
Dividendpercentage 0%
52-weken bereik 0.19 - 0.316
Industrie Biotechnology
Sector Healthcare
CEO Ms. Catharina Jz Johansson
Website https://abliva.com

An error occurred while fetching data.

Over Abliva AB (publ)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex

Vergelijkbare Aandelen

Saniona AB (publ) logo

Saniona AB (publ)

SANION.ST

2.105 SEK

Sprint Bioscience AB (publ) logo

Sprint Bioscience AB (publ)

SPRINT.ST

0.876 SEK

AlzeCure Pharma AB (publ) logo

AlzeCure Pharma AB (publ)

ALZCUR.ST

2.49 SEK

SenzaGen AB logo

SenzaGen AB

SENZA.ST

6.7 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)